What is Wolff‑Parkinson‑White syndrome in children and how is it acutely managed?

Wolff-Parkinson-White Syndrome in Children: Definition and Acute Management

For children with WPW syndrome presenting with hemodynamically unstable tachycardia, immediate electrical cardioversion is the life-saving intervention; for stable wide-complex pre-excited tachycardia, intravenous procainamide or ibutilide should be administered, while AV nodal blocking agents (adenosine, beta-blockers, calcium channel blockers, digoxin) are absolutely contraindicated as they can precipitate ventricular fibrillation and sudden death 1, 2.

What is Wolff-Parkinson-White Syndrome?

WPW syndrome is a congenital cardiac conduction abnormality where an accessory pathway (extra electrical connection) bypasses the normal AV node, creating an abnormal circuit between the atria and ventricles 3, 4. This manifests on ECG as:

• Delta wave (slurred upstroke of QRS complex)
• Short PR interval (<120 ms)
• Wide QRS complex (>120 ms)

The prevalence in children is approximately 0.1-0.3% of the general population, with neonatal incidence around 0.1-0.2% 5, 6. The condition is particularly dangerous because the accessory pathway can conduct impulses rapidly during atrial fibrillation, potentially degenerating into ventricular fibrillation and sudden cardiac death.

High-Risk Features in Children:

• Shortest pre-excited R-R interval <250 ms during atrial fibrillation
• History of syncope or near-syncope
• Multiple accessory pathways
• Symptomatic tachycardia episodes 1, 7, 8

The risk of sudden cardiac death ranges from 0.15-0.24% over 10 years, with highest risk in the first two decades of life 2, 6.

Acute Management Algorithm

Step 1: Assess Hemodynamic Stability

UNSTABLE (hypotension, altered consciousness, severe chest pain, heart failure):

• Immediate synchronized electrical cardioversion starting at 0.5-1 J/kg, increasing to 2 J/kg if ineffective 1, 2, 9
• This is Class I recommendation (Level of Evidence B) because of high risk of ventricular fibrillation
• Do not delay for sedation if patient is critically unstable

STABLE:

• Proceed to rhythm assessment and targeted therapy

Step 2: Identify the Rhythm Pattern

A. Narrow-Complex Tachycardia (QRS <120 ms) - Orthodromic AVRT:

This indicates conduction down through the AV node and back up through the accessory pathway.

1. First-line: Vagal maneuvers (Valsalva, carotid massage) 2

2. Second-line: Adenosine IV 0.1 mg/kg (max 6 mg) rapid push, followed by flush

   • Can repeat at 0.2 mg/kg (max 12 mg) 2, 9
   • CAUTION: Adenosine may precipitate atrial fibrillation with rapid ventricular response in WPW 7
   • Only use when QRS is narrow, confirming AV nodal involvement 1

3. If adenosine fails: Synchronized cardioversion 2

B. Wide-Complex Tachycardia (QRS ≥120 ms) - Pre-excited Tachycardia:

This indicates anterograde conduction over the accessory pathway (antidromic AVRT or pre-excited atrial fibrillation).

Pharmacologic options (Class I recommendation):

• Intravenous procainamide (preferred) 1, 2, 10
• Intravenous ibutilide 1, 2, 10

Alternative agents (Class IIb):

• Intravenous flecainide 10
• Quinidine, disopyramide, or amiodarone (less preferred) 1

These medications work by slowing conduction through the accessory pathway itself, not the AV node.

Step 3: CRITICAL - Avoid Dangerous Medications

Class III (CONTRAINDICATED) in pre-excited tachycardia or atrial fibrillation with WPW 1, 11, 1, 10, 12:

• Adenosine (in wide-complex tachycardia)
• Beta-blockers (IV administration)
• Calcium channel blockers (diltiazem, verapamil)
• Digoxin
• Amiodarone (specifically contraindicated in pre-excited AF) 12

Why these are dangerous: These agents block the AV node, which paradoxically encourages preferential conduction down the accessory pathway, potentially accelerating the ventricular rate to >300 bpm and precipitating ventricular fibrillation 1, 12.

Special Considerations in Pediatric Populations

Neonates and Infants:

• 43% of neonates show spontaneous resolution of delta wave 6
• However, 30% of WPW cases are diagnosed during infancy 6
• Recurrent episodes can cause tachycardia-induced cardiomyopathy 2
• Symptoms may be nonspecific: fussiness, poor feeding, vomiting, lethargy 13

Misdiagnosis Risk:

Recent case reports demonstrate WPW in children being misdiagnosed as malaria, gastroenteritis, or simple fussiness for months to years before correct diagnosis 3, 13. Any child with recurrent unexplained symptoms (chest discomfort, weakness, near-syncope, persistent fussiness) warrants ECG evaluation.

Asymptomatic Children:

• 29-47% of WPW patients are diagnosed incidentally 6
• Asymptomatic status does NOT guarantee safety
• Life-threatening event risk: 3.8 per 1000 person-years in South Wales cohort 6
• 8.1% of children presented with serious arrhythmia as first manifestation 6

Post-Acute Stabilization

Once acute episode is controlled:

1. 12-lead ECG to confirm WPW pattern (delta wave, short PR, wide QRS)

2. Cardiology consultation - mandatory for all pediatric WPW cases

3. Risk stratification via electrophysiology study (EPS) to measure:

   • Accessory pathway refractory period
   • Inducibility of arrhythmias
   • Presence of multiple pathways

4. Definitive treatment consideration: Catheter ablation is Class I recommendation for symptomatic patients, particularly those with:

   • Documented atrial fibrillation
   • Syncope suggesting rapid heart rate
   • Short bypass tract refractory period (<250 ms) 1, 11, 10

Success rate of catheter ablation exceeds 98.5% in experienced centers 8.

Common Pitfalls to Avoid

1. Administering AV nodal blockers in wide-complex tachycardia without confirming narrow QRS - this is the most dangerous error
2. Assuming asymptomatic WPW is benign - sudden death can be the first presentation
3. Treating recurrent symptoms as other conditions (malaria, gastroenteritis) without obtaining ECG
4. Using amiodarone in pre-excited atrial fibrillation - despite being an antiarrhythmic, it accelerates ventricular rate in this specific context 12
5. Delaying cardioversion in unstable patients to attempt pharmacologic conversion

The 2016 ACC/AHA/HRS guidelines 2 represent the most recent comprehensive guidance and should frame all management decisions, with the 2025 pediatric ACLS guidelines 9 providing specific pediatric dosing and algorithms.